Potent and orally efficacious bisthiazole-based histone deacetylase inhibitors

ACS Medicinal Chemistry Letters

Volumn 5, Issue 6, 2014, Pages 628-633

  Chen, Fei ^a   Chai, Hui ^a   Su, Ming Bo ^a   Zhang, Yang Ming ^a   Li, Jia ^a   Xie, Xin ^a   Nan, Fa Jun ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

bisthiazole; Histone deacetylase inhibitors; largazole

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; EMBRYO; ENZYME INHIBITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FIBROBLAST; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; MAXIMUM PLASMA CONCENTRATION; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL;

EID: 84902457915     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400470s     Document Type: Article

References (55)

1. Thiagalingam, S.; Cheng, K. H.; Lee, H. J.; Mineva, N.; Thiagalingam, A.; Ponte, J. F. Histone deacetylases: unique players in shaping the epigenetic histone code Ann. N.Y. Acad. Sci. 2003, 983, 84-100
2. Struhl, K. Histone acetylation and transcriptional regulatory mechanisms Genes. Dev. 1998, 12 (5) 599-606
3. Johnstone, R. W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer Nat. Rev. Drug. Discovery 2002, 1 (4) 287-99
4. Somech, R.; Izraeli, S.; A, J. S. Histone deacetylase inhibitors - a new tool to treat cancer Cancer Treat. Rev. 2004, 30 (5) 461-72
5. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors Nat. Rev. Drug. Discovery 2006, 5 (9) 769-84
6. Yang, X. J.; Seto, E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men Nat. Rev. Mol. Cell. Biol. 2008, 9 (3) 206-18
7. Imai, S.; Guarente, L. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases Trends Pharmacol. Sci. 2010, 31 (5) 212-20
8. Karagiannis, T. C.; El-Osta, A. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 2007, 21 (1) 61-5
9. Sweet, M. J.; Shakespear, M. R.; Kamal, N. A.; Fairlie, D. P. HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation Immunol. Cell Biol. 2012, 90 (1) 14-22
10. Dokmanovic, M.; Clarke, C.; Marks, P. A. Histone deacetylase inhibitors: overview and perspectives Mol. Cancer. Res. 2007, 5 (10) 981-9
11. Miller, T. A.; Witter, D. J.; Belvedere, S. Histone deacetylase inhibitors J. Med. Chem. 2003, 46 (24) 5097-116
12. Paris, M.; Porcelloni, M.; Binaschi, M.; Fattori, D. Histone deacetylase inhibitors: from bench to clinic J. Med. Chem. 2008, 51 (6) 1505-29
13. Newkirk, T. L.; Bowers, A. A.; Williams, R. M. Discovery, biological activity, synthesis and potential therapeutic utility of naturally occurring histone deacetylase inhibitors Nat. Prod. Rep. 2009, 26 (10) 1293-320
14. Sternson, S. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin Org. Lett. 2001, 3 (26) 4239-42
15. Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Pazdur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 2007, 12 (10) 1247-52
16. Campas-Moya, C. Romidepsin for the treatment of cutaneous T-cell lymphoma Drugs Today 2009, 45 (11) 787-95
17. Adcock, I. M. HDAC inhibitors as anti-inflammatory agents Br. J. Pharmacol. 2007, 150 (7) 829-31
18. Sospedra, M.; Martin, R. Immunology of multiple sclerosis Annu. Rev. Immunol. 2005, 23, 683-747
19. John, G. R.; Shankar, S. L.; Shafit-Zagardo, B.; Massimi, A.; Lee, S. C.; Raine, C. S.; Brosnan, C. F. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation Nat. Med. 2002, 8 (10) 1115-21
20. Hemmer, B.; Nessler, S.; Zhou, D.; Kieseier, B.; Hartung, H. P. Immunopathogenesis and immunotherapy of multiple sclerosis Nat. Clin. Pract. Neurol. 2006, 2 (4) 201-11
21. Matsuoka, H.; Fujimura, T.; Mori, H.; Aramori, I.; Mutoh, S. Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells Int. Immunopharmacol. 2007, 7 (11) 1422-32
22. Takahashi, I.; Miyaji, H.; Yoshida, T.; Sato, S.; Mizukami, T. Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase J. Antibiot. 1996, 49 (5) 453-7
23. Camelo, S.; Iglesias, A. H.; Hwang, D.; Due, B.; Ryu, H.; Smith, K.; Gray, S. G.; Imitola, J.; Duran, G.; Assaf, B.; Langley, B.; Khoury, S. J.; Stephanopoulos, G.; De Girolami, U.; Ratan, R. R.; Ferrante, R. J.; Dangond, F. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis J. Neuroimmunol. 2005, 164 (1-2) 10-21
24. Lv, J.; Du, C.; Wei, W.; Wu, Z.; Zhao, G.; Li, Z.; Xie, X. The antiepileptic drug valproic acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis J. Biol. Chem. 2012, 287 (34) 28656-65
25. Gough, N. R. Repurposing antiepileptic drugs for multiple sclerosis Science Signalling 2012, 5 (239) ec223
26. Taori, K.; Paul, V. J.; Luesch, H. Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp J. Am. Chem. Soc. 2008, 130 (6) 1806-7
27. Ying, Y.; Taori, K.; Kim, H.; Hong, J.; Luesch, H. Total synthesis and molecular target of largazole, a histone deacetylase inhibitor J. Am. Chem. Soc. 2008, 130 (26) 8455-9
28. Bowers, A.; West, N.; Taunton, J.; Schreiber, S. L.; Bradner, J. E.; Williams, R. M. Total synthesis and biological mode of action of largazole: a potent class I histone deacetylase inhibitor J. Am. Chem. Soc. 2008, 130 (33) 11219-22
29. Seiser, T.; Kamena, F.; Cramer, N. Synthesis and biological activity of largazole and derivatives Angew. Chem., Int. Ed. 2008, 47 (34) 6483-5
30. Ying, Y.; Liu, Y.; Byeon, S. R.; Kim, H.; Luesch, H.; Hong, J. Synthesis and activity of largazole analogues with linker and macrocycle modification Org. Lett. 2008, 10 (18) 4021-4
31. Bowers, A. A.; West, N.; Newkirk, T. L.; Troutman-Youngman, A. E.; Schreiber, S. L.; Wiest, O.; Bradner, J. E.; Williams, R. M. Synthesis and histone deacetylase inhibitory activity of largazole analogs: alteration of the zinc-binding domain and macrocyclic scaffold Org. Lett. 2009, 11 (6) 1301-4
32. Bowers, A. A.; Greshock, T. J.; West, N.; Estiu, G.; Schreiber, S. L.; Wiest, O.; Williams, R. M.; Bradner, J. E. Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole J. Am. Chem. Soc. 2009, 131 (8) 2900-5
33. Chen, F.; Gao, A. H.; Li, J.; Nan, F. J. Synthesis and biological evaluation of c7-demethyl largazole analogues ChemMedChem 2009, 4 (8) 1269-72
34. Souto, J. A.; Vaz, E.; Lepore, I.; Poppler, A. C.; Franci, G.; Alvarez, R.; Altucci, L.; de Lera, A. R. Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues J. Med. Chem. 2010, 53 (12) 4654-67
35. Nasveschuk, C. G.; Ungermannova, D.; Liu, X.; Phillips, A. J. A concise total synthesis of largazole, solution structure, and some preliminary structure activity relationships Org. Lett. 2008, 10 (16) 3595-8
36. Ghosh, A. K.; Kulkarni, S. Enantioselective total synthesis of (+)-largazole, a potent inhibitor of histone deacetylase Org. Lett. 2008, 10 (17) 3907-9
37. Ren, Q.; Dai, L.; Zhang, H.; Tan, W. F.; Xu, Z. S.; Ye, T. Total synthesis of largazole Synlett 2008, 15, 2379-2383
38. Numajiri, Y.; Takahashi, T.; Takagi, M.; Shin-Ya, K.; Doi, T. Total synthesis of largazole and its biological evaluation Synlett 2008, 16, 2483-2486
39. Wang, B.; Forsyth, C. J. Total synthesis of largazole: devolution of a novel synthetic strategy Synthesis-Stuttgart 2009, 17, 2873-2880
40. Zeng, X.; Yin, B.; Hu, Z.; Liao, C.; Liu, J.; Li, S.; Li, Z.; Nicklaus, M. C.; Zhou, G.; Jiang, S. Total synthesis and biological evaluation of largazole and derivatives with promising selectivity for cancers cells Org. Lett. 2010, 12 (6) 1368-71
41. Xiao, Q.; Wang, L. P.; Jiao, X. Z.; Liu, X. Y.; Wu, Q.; Xie, P. Concise total synthesis of largazole J. Asian Nat. Prod. Res. 2010, 12 (11) 940-9
42. Benelkebir, H.; Marie, S.; Hayden, A. L.; Lyle, J.; Loadman, P. M.; Crabb, S. J.; Packham, G.; Ganesan, A. Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability Bioorg. Med. Chem. 2011, 19 (12) 3650-8
43. Wang, B.; Huang, P. H.; Chen, C. S.; Forsyth, C. J. Total syntheses of the histone deacetylase inhibitors largazole and 2-epi-largazole: application of N -heterocyclic carbene mediated acylations in complex molecule synthesis J. Org. Chem. 2011, 76 (4) 1140-50
44. Cole, K. E.; Dowling, D. P.; Boone, M. A.; Phillips, A. J.; Christianson, D. W. Structural basis of the antiproliferative activity of largazole, a depsipeptide inhibitor of the histone deacetylases J. Am. Chem. Soc. 2011, 133 (32) 12474-7
45. Bhansali, P.; Hanigan, C. L.; Casero, R. A.; Tillekeratne, L. M. Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation J. Med. Chem. 2011, 54 (21) 7453-63
46. Li, X.; Tu, Z.; Li, H.; Liu, C.; Li, Z.; Sun, Q.; Yao, Y.; Liu, J.; Jiang, S. Biological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry ACS Med. Chem. Lett. 2012, 4 (1) 132-136
47. Diness, F.; Nielsen, D. S.; Fairlie, D. P. Synthesis of the thiazole-thiazoline fragment of largazole analogues J. Org. Chem. 2011, 76 (23) 9845-51
48. Pattenden, G.; Thom, S. M.; Jones, M. F. Enantioselective synthesis of 2-alkyl substituted cysteines Tetrahedron 1993, 49 (10) 2131-2138
49. Salmi-Smail, C.; Fabre, A. L.; Dequiedt, F.; Restouin, A.; Castellano, R. M.; Garbit, S.; Roche, P.; Morelli, X.; Brunel, J. M.; Collette, Y. Modified CAP group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity J. Med. Chem. 2010, 53 (8) 3038-3047
50. Chen, H. J.; Wang, W. L.; Wang, G. F.; Shi, L. P.; Gu, M.; Ren, Y. D.; Hou, L. F.; He, P. L.; Zhu, F. H.; Zhong, X. G.; Tang, W.; Zuo, J. P.; Nan, F. J. Rational design and synthesis of 2,2-bisheterocycle tandem derivatives as non-nucleoside hepatitis B virus inhibitors ChemMedChem 2008, 3 (9) 1316-21
51. Zhang, C.; Richon, V.; Ni, X.; Talpur, R.; Duvic, M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action J. Invest. Dermatol. 2005, 125 (5) 1045-52
52. Ruefli, A. A.; Ausserlechner, M. J.; Bernhard, D.; Sutton, V. R.; Tainton, K. M.; Kofler, R.; Smyth, M. J.; Johnstone, R. W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (19) 10833-8
53. Vrana, J. A.; Decker, R. H.; Johnson, C. R.; Wang, Z.; Jarvis, W. D.; Richon, V. M.; Ehinger, M.; Fisher, P. B.; Grant, S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53 Oncogene 1999, 18 (50) 7016-25
54. Lin, H. S.; Hu, C. Y.; Chan, H. Y.; Liew, Y. Y.; Huang, H. P.; Lepescheux, L.; Bastianelli, E.; Baron, R.; Rawadi, G.; Clement-Lacroix, P. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents Br. J. Pharmacol. 2007, 150 (7) 862-872
55. Dinarello, C. A.; Fossati, G.; Mascagni, P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer Mol. Med. 2011, 17 (5-6) 333-52